Class: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Mechanism of Action: It mimics the action of the GLP-1 hormone, which increases insulin secretion, slows gastric emptying, and reduces appetite.
Uses: It is primarily used for the treatment of type 2 diabetes but has been approved for weight loss in certain cases.
Administration: Semaglutide is available as a weekly injection.
Effectiveness: In clinical trials, semaglutide has been shown to help individuals lose a significant amount of weight when combined with lifestyle changes such as diet and exercise.
Tirzepatide
Class: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.
Mechanism of Action: It targets both GIP and GLP-1 receptors, which results in improved insulin secretion, decreased appetite, slowed gastric emptying, and enhanced fat oxidation.
Uses: Like semaglutide, tirzepatide is used for the treatment of type 2 diabetes and has shown promise in weight loss management.
Administration: Tirzepatide is administered as a weekly injection, similar to semaglutide.
Effectiveness: Clinical trials have shown that tirzepatide can result in more significant weight loss compared to semaglutide. Its dual action on GIP and GLP-1 receptors provides a potentially more robust metabolic effect.